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Those results also indicated that the alveolar epithelium, in addition to the capillary endothelium, can be a producer of ANG II under conditions that promote the presence of these cytokines. The lung myofibroblast, which accumulates in fibrotic human lung and in animal models of lung fibrosis (17) , also synthesizes the precursor of ANG II, the 58-kDa proprotein angiotensinogen (20) . Although isolated human lung myofibroblasts have little capacity to proteolytically process the parent protein, related studies have shown that AEC can convert the parent molecule to ANG II and respond to it by undergoing apoptosis (22) . For all these reasons, the mechanisms by which ANG II interacts with AEC are critical to understanding the regulation of cell death in the alveolar epithelium.
Apoptosis of AEC induced by purified ANG II could be completely abrogated by ANG II-neutralizing antibodies or by the nonselective ANG receptor antagonist saralasin (22) . Analyses of total RNA by RT-PCR indicated that both the A549 cell line and primary AEC from rats express the mRNAs for the two major subtypes of the ANG receptor, AT 1 and AT 2 . Evidence from other cell types indicate that either or both of these subtypes may be involved in signaling apoptosis, depending on the cell type in question and the experimental conditions. Moreover, the relative importance of the AT 1 vs. the AT 2 receptors in signaling apoptosis can change in a manner dependent on other stimuli (5) .
The purpose of the present study, therefore, was to determine the relative importance of the ANG receptor subtypes AT 1 and AT 2 in the induction of AEC apoptosis with well-differentiated primary cultures of normal AEC in the absence of additional stimuli. We report here the use of functional assays and subtype-selective receptor antagonists to determine that the ANG recep-tor subtype AT 1 mediates AEC apoptosis, under basal conditions, in a manner apparently independent of receptor subtype AT 2 .
MATERIALS AND METHODS
Reagents and materials. The AT1-selective antagonists L-158809 and losartan were obtained from Merck (West Point, PA). The AT 2-selective antagonists PD-126055 and PD-123319 were obtained from Parke Davis Research Division (Ann Arbor, MI). The caspase inhibitor ZVAD-fmk (N-benzylcarboxy-Val-Ala-Asp-fluoromethylketone) was obtained from Kamiya Biomedical (Seattle, WA). DEVD-fmk (Asp-Glu-Val-Asp-fluoromethylketone) and YVAD-cmk (Tyr-Val-Ala-Asp-chloromethylketone) were obtained from Pharmingen (San Diego, CA). Alkaline phosphatase-conjugated streptavidin, digoxigenin-labeled deoxyuridine trisphosphate, and biotinylated deoxyuridine trisphosphate were obtained from Boehringer Mannheim (Indianapolis, IN) . Antiphosphotyrosine antibodies were obtained from Upstate Biotechnology (Saranac Lake, NY). Reagents for detection of alkaline phosphatase and other secondary reagents for in situ end labeling (ISEL) of DNA or Western blotting were from sources described earlier (16) . All other materials were of reagent grade and were obtained from Sigma Chemical (St. Louis, MO).
Cell culture. The human lung adenocarcinoma cell line A549 was obtained from American Type Culture Collection and cultured in Ham's F-12 medium supplemented with 10% fetal bovine serum. Primary AEC were isolated from adult male Wistar rats as described earlier (17) . The primary cells were studied at day 2 of culture, a time at which they are type II cell-like by accepted morphological and biochemical criteria (14) . All primary cell preparations were of better than 90% purity assessed by acridine orange staining as described previously (15) . All cells were seeded in 24-well chambers at subconfluent densities of 80-90% in serum-free Ham's F-12 medium. Test reagents were diluted with Ham's F-12 medium. The cells were exposed to caspase inhibitors, chelerythrine, sodium orthovanadate, or antagonists of angiotensin receptors 30 min before exposure to ANG II for 20 h.
Quantitations of apoptosis and cell loss. Detection of apoptotic cells with propidium iodide (PI) was conducted as described earlier (19, 21) after digestion of ethanol-fixed cells with DNase-free RNase in PBS containing 5 g/ml of PI. In these assays, detached cells were retained by centrifugation of the 24-well culture vessels during fixation with 70% ethanol. Cells with discrete nuclear fragments containing condensed chromatin were scored as apoptotic. As in earlier publications, the induction of apoptosis was verified by annexin V binding (19, 22) and by ISEL and/or TdT-mediated dUTP nick end labeling (TUNEL) of fragmented DNA (16, 17 ) (see Fig. 1 ). Apoptotic cells were scored over a minimum of four separate microscopic fields from each of at least three culture vessels per treatment group.
Cell loss over 20 h of culture was quantitated by cell counts of the adherent and detached cell populations. These were obtained after centrifugation of the culture vessels as described in the preceding paragraph, without prior washing. Thus detached cells (routinely Ͻ10% of the total cell number) were included in the cell loss data. Total cell counts (attached plus detached) were scored over a minimum of 200 nuclei per field, four fields per well, with a minimum of six culture wells or 4,800 nuclei per treatment group. Data from each treatment group were compiled and analyzed by ANOVA followed by Student-Newman-Keuls post hoc analysis.
Western blotting. Total protein lysates were obtained from AEC scraped from the culture vessels in Nonidet P-40 lysis buffer supplemented with a commercially available protease inhibitor cocktail. Proteins were resolved on 12% ReadyGels (Bio-Rad), transferred to polyvinylidene difluoride blotting membranes, and incubated with anti-phosphotyrosine polyclonal antibodies. Bound primary antibody was detected with biotin-conjugated secondary antibodies and a streptavidinchromogen amplification system (20) .
RESULTS
Previous studies of the ability of ANG II to induce apoptosis in human and rat AEC (22) revealed a dosedependent induction that became maximal at ANG II concentrations of 5 M and higher. For this reason, the single concentration of 5 M ANG II was used to test the ability of various inhibitors to block ANG II-induced apoptosis. The assay of nuclear fragmentation revealed by PI (Fig. 1A, arrows) was shown to detect the same nuclear fragments that label by ISEL (Fig.  1A, top inset) or by TUNEL (bottom inset), each applied after exposure of AEC to ANG II. In Fig. 1B , the caspase inhibitors ZVAD-fmk, DEVD-fmk, and YVADcmk blocked apoptosis in response to ANG II, although to varying degrees that are expressed as percent inhibition relative to ANG II alone (Fig. 1B, inset) . The apoptotic indexes detected under these conditions were 1.8 Ϯ 0.2% vs. 8.8 Ϯ 1.1% (control vs. ANG II, respectively).
Over 20 h of incubation, this level of apoptosis induction was sufficient to reduce the total cell number (attached ϩ detached) in a given culture vessel by Ͼ50% (Fig. 1C) . These results are consistent with an estimated duration of AEC apoptosis of ϳ4-5 h, which is in agreement with that reported by Bursch et al. (2) in their kinetic study of hepatocyte apoptosis. The net decrease in cell number induced by ANG II was blocked by either ZVAD-fmk (60 M), by the nonselective ANG II receptor antagonist saralasin (50 g/ml), or by the receptor AT 1 -selective antagonist L-158809 (10 Ϫ9 M). Without additives, cell number was constant during the 20-h incubation (compare time 0 with control at 20 h), confirming the absence of cell proliferation (15) .
Under the same experimental conditions, application of subtype-selective ANG receptor antagonists revealed complete abrogation of ANG-induced apoptosis by the AT 1 -selective antagonist L-158809 in either primary cultures of rat AEC (Fig. 2) or in the human A549 carcinoma cell line (Fig. 3) . In contrast, the AT 2 -selective antagonist PD-126055 (Figs. 2B and 3B) did not achieve statistically significant inhibition, at any concentration, compared with treatment with ANG II alone (as in Fig. 1B) . The inhibition by L-158809 was maximal at 10 Ϫ8 M in both cell types but exhibited a slightly lower IC 50 in primary rat AEC (10 Ϫ12 M) than in A549 cells (10 Ϫ11 M). In primary cultures of rat AEC, qualitatively similar results were obtained with additional antagonists. The AT 1 -selective receptor blocker losartan (Fig. 4A) completely inhibited ANG II-induced apoptosis at 10 Ϫ8 M, but the AT 2 -selective antagonist PD-123319 had no statistically significant inhibitory effect. Losartan exhibited an IC 50 for ANG II-induced apoptosis of ϳ10 Ϫ11 M. In other cell types, the action of the ANG II receptor subtype AT 1 is mediated, at least in part, by protein kinase C (PKC), whereas the action of AT 2 is dependent on protein tyrosine phosphatases. Consistent with those observations, the PKC inhibitor chelerythrine (Fig. 5) showed dose-dependent inhibition of ANGinduced apoptosis in primary rat AEC with an IC 50 of ϳ0.5 M. In contrast, the tyrosine phosphatase inhib- itor sodium orthovanadate (SOV; Fig. 6A ) had no inhibitory capacity toward AEC apoptosis at any concentration up to 1 mM, despite the ability of 100 M SOV to significantly increase the abundance of phosphotyrosine residues on AEC proteins observed by Western blotting (Fig. 6B) .
DISCUSSION
The induction of apoptosis by ANG II has been studied most extensively in cardiac myocytes (3, 7, 10, 11) , in capillary endothelial cells (4, 12) , and in some transformed cell lines (9, 23) . To date, the issue of which ANG receptor subtype mediates the induction of apoptosis is controversial and highly dependent on the type of experimental system under study. Investigations of transformed R3T3 and phaeochromocytoma PC12W cells (9, 23) , which express primarily the AT 2 receptor subtype, suggested that AT 2 is the mediator of apoptosis in response to ANG II. In the cardiac myocyte system, however, neonatal ventricular myocytes undergo ANG II-induced apoptosis that was abrogated by AT 1 -selective blockers but not by AT 2 -selective antag- onists (3, 11) . The same blockade of ANG II-mediated apoptosis by AT 1 -selective antagonists, but not by AT 2 -selective antagonists, was also observed in adult ventricular myocytes in the studies of Kajstura et al. (10) . These data are in contrast with those of other investigators, who found essentially the opposite result using the neonatal myocyte culture system (6) .
In cultured human coronary artery endothelial cells, the AT 1 -selective antagonist losartan blocked apoptosis in response to ANG II, TNF-␣, and anoxia reoxygenation applied simultaneously (12) . In contrast, the AT 2 -selective agonist CGP-42112 induced apoptosis of cultured coronary endothelial cells (13) , but neither AT 1 -nor AT 2 -selective antagonists could block ANG II-induced apoptosis in that study. Moreover, Dimmeler et al. (4) found that AT 1 -and AT 2 -selective antagonists could block apoptosis in human umbilical vein endothelial cells when the agents were applied together.
The interpretation of these studies is complicated by the fact that an unusually high dose of the AT 2 agonist CGP-42112 (2 mM) was required for the induction of apoptosis in coronary artery cells (13) ; the normal serum concentration of ANG II is ϳ1-10 pM (5). Thus it is possible that the partial AT 1 agonist activity of this otherwise AT 2 -selective compound was acting through the AT 1 receptor. Moreover, studies in which the AT 2 receptor has been implicated as the primary mediator of apoptosis have generally been conducted with cell lines that express AT 2 , but little or no AT 1 , receptor (9, 23) . Together, the available data imply that the ANG receptor subtype most important in mediating apoptosis in a given cell type is likely dependent on the relative expression of AT 1 vs. AT 2 .
Regardless, the ability of AT 1 -selective antagonists to block ANG-induced apoptosis in the present study clearly suggests that AT 1 is the functional receptor for apoptosis in normal AEC, despite the expression by these cells of both mRNAs for AT 1 and AT 2 (22) . This interpretation is supported by the finding that the benzophenanthridine alkaloid chelerythrine, a specific inhibitor of PKC (8), could block AEC apoptosis, but an inhibitor of tyrosine phosphatases (SOV) could not. The presumption that the SOV treatment actually blocked tyrosine phosphatase activity but not apoptosis is supported by the large increases in phosphotyrosines detected by Western blotting of AEC proteins (Fig. 6B) . In other cell types, AT 1 -mediated effects have been demonstrated to involve PKC activation (10, 12) , whereas AT 2 signaling is believed to be mediated by a protein tyrosine phosphatase(s) inhibitable by SOV (1, 23) . Together, the failure of SOV and the success of chelerythrine to inhibit ANG II-induced apoptosis support the conclusion that receptor subtype AT 1 is active in mediating AEC apoptosis, at least under challenge by purified ANG II. Evaluation of ANG receptor specificity after exposure of AEC to Fas ligand or TNF-␣, both of which require ANG II receptor interaction for the induction of apoptosis (19, 21) , will be an interesting topic for future inquiry.
In summary, apoptosis of AEC in response to purified ANG II was inhibited by the AT 1 -selective antagonists L-158809 or losartan in a concentration-dependent manner, but not by the AT 2 -selective antagonists PD-123319 or PD-126055. A PKC inhibitor (chelerythrine) known to block AT 1 receptor signaling in other cell types inhibited ANG II-stimulated apoptosis of AEC. However, an inhibitor of protein tyrosine phosphatases (SOV) known to block AT 2 signaling had no effect on ANG II-induced apoptosis of AEC. These data indicate that receptor subtype AT 1 mediates apoptosis of AEC in response to ANG II in the absence of additional stimuli. Fig. 6 . Inhibition of tyrosine phosphatases has no effect on ANG II-induced apoptosis in primary rat AEC. A: primary isolates of rat AEC were incubated in serum-free medium containing purified ANG II (5 M) or the indicated concentrations of the tyrosine phosphatase inhibitor sodium orthovanadate (SOV). Data are from the PI assay. Bars are means Ϯ SE of at least 12 determinations. All values (except first bar) are not significantly different from ANG II alone by ANOVA and Student-Newman-Keuls post hoc test. B: primary isolates of rat AEC were incubated in serum-free medium containing purified ANG II at 5 M (ANG) in the presence and absence of 100 M SOV for 20 h. In the presence of SOV, Western blotting of AEC total protein lysates shows significant increases in the abundance of phosphotyrosine residues on proteins of 43-160 kDa (arrowheads).
